Yamo Pharmaceuticals

Yamo Pharmaceuticals is developing L1-79, a novel therapy targeting core symptoms of autism, which has so far shown good tolerability in clinical trial patients. The mechanism of action of L1-79 involves both the central nervous system and metabolic symptoms associated with autism.